Babak Saboury

Dr. Babak Saboury

National Institutes of Health (NIH)
orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 March 2011 in Science
Verified
Journal Article
Closed access
PDF file
GBGregory L. Beatty
Gregory L. Beatty
ECElena G. Chiorean
Elena G. Chiorean
MFMatthew P. Fishman
Matthew P. Fishman
Babak SabouryBabak Saboury
Babak Saboury
UTUrsina R. Teitelbaum
Ursina R. Teitelbaum
RVRobert H. Vonderheide
Robert H. Vonderheide
CD40 immunotherapy shows efficacy in treating pancreatic cancer in mice and humans by eliciting antitumor immunity.

14 November 2013 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
GBGregory L. Beatty
Gregory L. Beatty
DTDrew A. Torigian
Drew A. Torigian
ECE. Gabriela Chiorean
E. Gabriela Chiorean
Babak SabouryBabak Saboury
Babak Saboury
ABAlex Brothers
Alex Brothers
POPeter J. O'Dwyer
Peter J. O'Dwyer
Purpose: This phase I study investigated the maximum-tolerated dose (MTD), safety, pharmacodynamics, immunologic correlatives, and antitumor activity of CP-870,893, an agonist CD40 antibody, when administered in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma (PDA). Experimental Design: Twenty-two patients with chemotherapy-naïve advanced PDA were treated with 1,000 mg/m2 gemcitabine once weekly for three weeks with infusion of CP-870,893 at 0.1 or 0.2 mg/kg on day three of each 28-day cycle. Results: CP-870,893 was well-tolerated; one dose-limiting toxicity (grade 4, cerebrovascular accident) occurred at the 0.2 mg/kg dose level, which was estimated as the MTD. The most common adverse event was cytokine release syndrome (grade 1 to 2). CP-870,893 infusion triggered immune activation marked by an increase in inflammatory cytokines, an increase in B-cell expression of costimulatory molecules, and a transient depletion of B cells. Four patients achieved a partial response (PR). 2-[18F]fluoro-2-deoxy-d-glucose-positron emission tomography/computed tomography (FDG-PET/CT) showed more than 25% decrease in FDG uptake within primary pancreatic lesions in six of eight patients; however, responses observed in metastatic lesions were heterogeneous, with some lesions responding with complete loss of FDG uptake, whereas other lesions in the same patient failed to respond. Improved overall survival correlated with a decrease in FDG uptake in hepatic lesions (R = −0.929; P = 0.007). Conclusions: CP-870,893 in combination with gemcitabine was well-tolerated and associated with antitumor activity in patients with PDA. Changes in FDG uptake detected on PET/CT imaging provide insight into therapeutic benefit. Phase II studies are warranted. Clin Cancer Res; 19(22); 6286–95. ©2013 AACR.

1 April 2013 in Radiology
Verified
Journal Article
Closed access
DTDrew A. Torigian
Drew A. Torigian
Habib ZaidiHabib Zaidi
Habib Zaidi
TKThomas C. Kwee
Thomas C. Kwee
Babak SabouryBabak Saboury
Babak Saboury
JUJayaram K. Udupa
Jayaram K. Udupa
AAAbass Alavi
Abass Alavi
PET/MR imaging offers the potential for a powerful “onestop shop” combination of structural, functional, and molecular imaging technologies that may be superior to PET/CT, PET alone, or MR imaging alone for certain clinical applications. Instruments that combine positron emission tomography (PET) and magnetic resonance (MR) imaging have recently been assembled for use in humans, and may have diagnostic performance superior to that of PET/computed tomography (CT) for particular clinical and research applications. MR imaging has major strengths compared with CT, including superior soft-tissue contrast resolution, multiplanar image acquisition, and functional imaging capability through specialized techniques such as diffusion-tensor imaging, diffusion-weighted (DW) imaging, functional MR imaging, MR elastography, MR spectroscopy, perfusion-weighted imaging, MR imaging with very short echo times, and the availability of some targeted MR imaging contrast agents. Furthermore, the lack of ionizing radiation from MR imaging is highly appealing, particularly when pediatric, young adult, or pregnant patients are to be imaged, and the safety profile of MR imaging contrast agents compares very favorably with iodinated CT contrast agents. MR imaging a...

1 September 2011 in Archives of Dermatology
Verified
Journal Article
Open access
PDF file
NMNehal N. Mehta
Nehal N. Mehta
YYYiDing Yu
YiDing Yu
Babak SabouryBabak Saboury
Babak Saboury
NFNegar Foroughi
Negar Foroughi
PKParasuram Krishnamoorthy
Parasuram Krishnamoorthy
JGJoel M. Gelfand
Joel M. Gelfand
Psoriasis is a chronic inflammatory disease affecting 2% to 3% of the adult population.1,2 It is associated with an inflammatory arthritis (psoriatic arthritis) in about 10% of patients, with much higher frequencies in patients with more extensive skin disease.3 Psoriasis is also associated with increases in markers of inflammation in the skin and blood and increasingly is thought to be a systemic inflammatory disease and risk factor for incident diabetes mellitus, myocardial infarction, stroke, and premature cardiovascular (CV) death.4-18 The mechanism behind these associated comorbidities, however, remains unknown. It has been widely suggested that a possible common pathway linking psoriasis to metabolic and CV disease is chronic inflammation mediated by TH17 and TH1 cells.19-23 Yet, despite evidence of systemic inflammation in psoriasis, few techniques have been successfully used to identify and quantify locations of inflammation in vivo in these patients. Because traditional markers of systemic inflammation, such as high-sensitivity C-reactive protein (hsCRP) and erythrocyte sedimentation rate, only modestly correlate with psoriasis severity and do not provide regional information about disease involvement, novel assessments of inflammation in vivo are particularly important in understanding the impact of psoriasis on systemic inflammation and systemic comorbidities.24

24 October 2011 in Alzheimer's & Dementia
Verified
Journal Article
Closed access
EMErik S. Musiek
Erik S. Musiek
YCYufen Chen
Yufen Chen
MKMarc Korczykowski
Marc Korczykowski
Babak SabouryBabak Saboury
Babak Saboury
PMPatricia M. Martinez
Patricia M. Martinez
JDJohn A. Detre
John A. Detre

27 July 2023 in Nature Medicine
Verified
Journal Article
Open access
PDF file
RHRaffit Hassan
Raffit Hassan
MBMarcus Butler
Marcus Butler
RORoisin O'cearbhaill
Roisin O'cearbhaill
DODavid Y. Oh
David Y. Oh
MJMelissa Johnson
Melissa Johnson
DHDavid S. Hong
David S. Hong
The T cell receptor fusion construct (TRuC) gavocabtagene autoleucel (gavo-cel) consists of single-domain anti-mesothelin antibody that integrates into the endogenous T cell receptor (TCR) and engages the signaling capacity of the entire TCR upon mesothelin binding. Here we describe phase 1 results from an ongoing phase1/2 trial of gavo-cel in patients with treatment-refractory mesothelin-expressing solid tumors. The primary objectives were to evaluate safety and determine the recommended phase 2 dose (RP2D). Secondary objectives included efficacy. Thirty-two patients received gavo-cel at increasing doses either as a single agent (n = 3) or after lymphodepletion (LD,n = 29). Dose-limiting toxicities of grade 3 pneumonitis and grade 5 bronchioalveolar hemorrhage were noted. The RP2D was determined as 1 × 108cells per m2after LD. Grade 3 or higher pneumonitis was seen in 16% of all patients and in none at the RP2D; grade 3 or higher cytokine release syndrome occurred in 25% of all patients and in 15% at the RP2D. In 30 evaluable patients, the overall response rate and disease control rate were 20% (13% confirmed) and 77%, respectively, and the 6-month overall survival rate was 70%. Gavo-cel warrants further study in patients with mesothelin-expressing cancers given its encouraging anti-tumor activity, but it may have a narrow therapeutic window. ClinicalTrials.gov identifier:NCT03907852.